Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | HTR1D | P28221 | 2/20 | 1.00 |
| ▸ | HTR1B | P28222 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR1E | P28566 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | APAF1 | O14727 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274268 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL5739268 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL29886359 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR1AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL274201 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR1AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL27539521 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR1AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL30729369 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR1AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL8655108 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR1AHTR1DHTR1B | |
| Cyanide SCHEMBL28931854 | 0.95 | HTR2A (0.90) | HTR2AHTR2CHTR1AHTR1DHTR1B | |
| Acetic Acid SCHEMBL264322 | 0.91 | HTR2A (0.82) | HTR2AHTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL4206927 | 0.89 | HTR2A (0.80) | HTR2AHTR2CHTR1AHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12233052-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2025-02-25 | — | — | US | claimed |
| CN-112375078-B | Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2023-12-19 | — | — | CN | claimed |
| US-20230045776-A9 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | claimed |
| CN-113862234-A | Transaminase and application thereof in preparation of (R) -alpha-methyltryptamine compounds | 弈柯莱生物科技(上海)股份有限公司 | 2021-12-31 | — | — | CN | claimed |
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | OLEMA PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260103461-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | OLEMA PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3760623-B1 | TETRAHYDRO-PYRIDO[3,4-B]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-20250388590-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-b]INDOLES | HOFFMANN-LA ROCHE INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448386-B2 | Processes for the preparation of substituted 1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indoles | HOFFMANN-LA ROCHE INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4629971-A1 | DOSAGE FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST | Olema Pharmaceuticals, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12370181-B2 | Regimens of estrogen receptor antagonists | OLEMA PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4114391-B1 | COMPOSITIONS FOR USE IN A METHOD OF TREATING AN ESTROGEN RECEPTOR ASSOCIATED CANCER | OLEMA PHARMACEUTICALS INC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-7217728-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070066586-A1 | ANILINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2007-03-22 | — | — | US | disclosed |
| US-6042824-A | COMBINING THE SUBSTRATE AND A CROSSLINKED ENZYME CRYSTAL FORMULATION CONTAINING A CROSSLINKED ENZYME AND A SURFACTANT WHICH ACTS UPON THE SUBSTRATE IN PRESENCE OF ORGANIC SOLVENT OR AQUEOUS-ORGANIC SOLVENT TO FORM A PRODUCT | ALTUS BIOLOGICS, INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5932212-A | BLEND CONTAINING SURFACTANT; BIOCATALYST | ALTUS BIOLOGICS, INC. (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0906417-A1 | CROSS-LINKED PROTEIN CRYSTAL FORMULATIONS AND THEIR USE AS CATALYSTS IN ORGANIC SOLVENTS | Altus Biologics Inc. (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997044445-A1 | CROSS-LINKED PROTEIN CRYSTAL FORMULATIONS AND THEIR USE AS CATALYSTS IN ORGANIC SOLVENTS | ALTUS BIOLOGICS INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| US-5030640-A | Alpha-heterocyclic ethanolamino alkylindoles, growth promoters and feed efficiency agents for animals, bronchodilators, antidepressants, antiobesity agents | MERCK & CO., INC. (US) | 1991-07-09 | — | — | US | disclosed |
| US-4806655-A | Process for the stereospecific synthesis of indole derivatives | SOCIETE ANONYME: SANOFI (FR) | 1989-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233052-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | ESR2, GPER1, ESR1 | HTR2A 41/4885HTR2C 26/4885HTR1A 27/4885 |
| US-20250388590-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-b]INDOLES | SLC6A9, SLC6A1, SLC9A1 | HTR2A 1260/4885HTR2C 212/4885HTR1A 328/4885 |
| US-20260103461-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESRRA, GPER1, ESR2 | HTR2A 464/4885HTR2C 406/4885HTR1A 429/4885 |
| US-12370181-B2 | Regimens of estrogen receptor antagonists | ESR1, GPER1, ESR2 | HTR2A 38/4885HTR2C 47/4885HTR1A 59/4885 |
| US-20070066586-A1 | ANILINE DERIVATIVES | SERPINB1, ACE, REN | HTR2A 669/4885HTR2C 426/4885HTR1A 659/4885 |
| US-12448386-B2 | Processes for the preparation of substituted 1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indoles | WEE1, WEE2, PGK1 | HTR2A 337/4885HTR2C 68/4885HTR1A 243/4885 |
| US-20230045776-A9 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | HTR2A 41/4885HTR2C 26/4885HTR1A 27/4885 |
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | ESR1, ESR2, PGR | HTR2A 431/4885HTR2C 215/4885HTR1A 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.